Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions: DRUG: Entinostat
Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: Syndax Pharmaceuticals|National Cancer Institute (NCI)